Additionally, binding of CTLA-4 to CD80/86 on dendritic cells can result in functional suppression of dendritic cells (57).Ipilimumab, a monoclonal antibody targeting CTLA-4 developed in 2011, was approved by the U.S. Food and Drug Administration (FDA) as the first-line immunotherapy for the treatment of melanoma (58). This evidence concerns the gene CD80 and melanoma.